First-in-human studies in 2026: More complex, more regulated, more global
By Nucleus Network
Download this free report for an in-depth look at the three key forces that are reshaping early-phase research in 2026, each with the potential to add cost, time and risk if not managed effectively.
The first-in-human study has quietly changed character. What was once a contained exercise in establishing initial safety and pharmacokinetics now carries far more scientific and commercial weight, and with that weight comes complexity. This report examines those complexities in detail, highlighting how each of these challenges is not a reason to slow down, but a problem that the right approach and support can help solve.
Download now to find out more.